Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ZURA
- Price
- 1.13
- Stock movement down
- -0.02 (-1.74%)
- Company name
- Zura Bio Limited Class A Ordinary Shares
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 72.06M
- Ent value
- -97.91M
- Price/Sales
- -
- Price/Book
- 0.42
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -58.61%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-09
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ZURA does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 0.42 |
| EV to Sales | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 63.77M |
| EPS (TTM) | -0.49 |
| FCF per share (TTM) | -0.30 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -1.00K |
| Operating income (TTM) | -50.28M |
| Net income (TTM) | -42.57M |
| EPS (TTM) | -0.49 |
| EPS (1y forward) | -0.74 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 188.22M |
| Net receivables | 0.00 |
| Total current assets | 188.97M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 189.07M |
| Accounts payable | 1.01M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 18.24M |
| Total liabilities | 18.24M |
| Shareholder's equity | 170.83M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -21.30M |
| Capital expenditures (TTM) | 5.03M |
| Free cash flow (TTM) | -26.34M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -24.92% |
| Return on Assets | -22.52% |
| Return on Invested Capital | -24.92% |
| Cash Return on Invested Capital | -15.42% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.20 |
| Daily high | 1.23 |
| Daily low | 1.13 |
| Daily Volume | 331K |
| All-time high | 33.21 |
| 1y analyst estimate | 15.00 |
| Beta | 0.14 |
| EPS (TTM) | -0.49 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| ZURA | S&P500 | |
| Current price drop from All-time high | -96.60% | -19.00% |
| Highest price drop | -96.90% | -56.47% |
| Date of highest drop | 4 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -85.47% | -11.07% |
| Avg time to new high | 172 days | 12 days |
| Max time to new high | 513 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
72.06M
Marketcap category
Small-cap
Description
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.
Employees
14
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page